In the June issue of
Managing Intellectual Property, the publication recognized Finnegan partner
Charles E. Lipsey as one of the top ten U.S. litigators in the life sciences patent industry. Representative matters that Mr. Lipsey worked on include
University of California v. Eli Lilly and Co., where Finnegan successfully defended Lilly’s human insulin product from infringement allegations, and
Eli Lilly & Co. v. Zenith Goldline Pharms, in which Finnegan successfully obtained for Lilly determination of infringement and validity of a patent on the drug product Zyprexa®.